Organogenesis Capex To Revenue vs Cost Of Revenue Analysis

ORGO Stock

USD 4.05 0.03 0.75%

Organogenesis Holdings financial indicator trend analysis is much more than just breaking down Organogenesis Holdings prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Organogenesis Holdings is a good investment. Please check the relationship between Organogenesis Holdings Capex To Revenue and its Cost Of Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.

Capex To Revenue vs Cost Of Revenue

Capex To Revenue vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Organogenesis Holdings Capex To Revenue account and Cost Of Revenue. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Organogenesis Holdings' Capex To Revenue and Cost Of Revenue is 0.82. Overlapping area represents the amount of variation of Capex To Revenue that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Organogenesis Holdings, assuming nothing else is changed. The correlation between historical values of Organogenesis Holdings' Capex To Revenue and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Revenue of Organogenesis Holdings are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Capex To Revenue i.e., Organogenesis Holdings' Capex To Revenue and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

0.82

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Cost Of Revenue

Cost of Revenue is found on Organogenesis Holdings income statement and represents the costs associated with goods and services Organogenesis Holdings provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from Organogenesis Holdings' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Organogenesis Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.At this time, Organogenesis Holdings' Tax Provision is very stable compared to the past year. As of the 22nd of November 2024, Sales General And Administrative To Revenue is likely to grow to 0.68, while Selling General Administrative is likely to drop about 149.1 M.

	2021	2022	2023	2024 (projected)
Cost Of Revenue	114.2M	105.0M	123.4M	69.0M
Research Development	30.7M	39.8M	44.4M	46.6M

Cost Of Revenue Research Development

Organogenesis Holdings fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Long Term Debt	Net Receivables	Good Will	Common Stock Total Equity	Retained Earnings Total Equity	Short Term Investments	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment
Total Assets		0.78	0.77	0.92	0.13	0.73	-0.34	0.84	0.82	0.56	0.16	0.86	0.85	0.26	0.41	0.43	0.75	0.71	0.8	0.8	0.67	0.82	0.72	0.64	0.26	0.7
Other Current Liab	0.78		0.86	0.56	0.23	0.77	-0.51	0.79	0.92	0.71	-0.04	0.9	0.79	-0.24	0.41	0.25	0.79	0.69	0.9	0.87	0.59	0.92	0.75	0.66	-0.24	0.62
Total Current Liabilities	0.77	0.86		0.47	0.16	0.79	-0.72	0.88	0.93	0.53	-0.1	0.89	0.9	-0.34	0.4	0.38	0.8	0.78	0.99	0.99	0.54	0.95	0.8	0.64	-0.34	0.65
Total Stockholder Equity	0.92	0.56	0.47		0.09	0.54	-0.04	0.62	0.56	0.43	0.24	0.65	0.64	0.57	0.32	0.38	0.55	0.52	0.5	0.51	0.6	0.55	0.53	0.51	0.57	0.58
Other Liab	0.13	0.23	0.16	0.09		-0.24	-0.58	0.16	0.06	-0.24	0.1	0.0	0.37	0.24	-0.49	0.08	0.26	-0.09	0.18	0.13	-0.41	0.06	-0.07	0.64	0.24	-0.22
Net Tangible Assets	0.73	0.77	0.79	0.54	-0.24		-0.26	0.74	0.87	0.51	-0.1	0.87	0.69	-0.34	0.73	0.28	0.7	0.95	0.82	0.8	0.87	0.87	0.95	0.34	-0.34	0.89
Retained Earnings	-0.34	-0.51	-0.72	-0.04	-0.58	-0.26		-0.54	-0.53	-0.08	0.16	-0.38	-0.63	0.29	0.06	-0.09	-0.51	-0.35	-0.68	-0.7	0.13	-0.55	-0.33	-0.6	0.29	-0.1
Accounts Payable	0.84	0.79	0.88	0.62	0.16	0.74	-0.54		0.89	0.55	0.35	0.93	0.93	-0.14	0.23	0.61	0.92	0.76	0.9	0.91	0.65	0.9	0.72	0.72	-0.14	0.78
Cash	0.82	0.92	0.93	0.56	0.06	0.87	-0.53	0.89		0.65	0.01	0.96	0.83	-0.32	0.51	0.38	0.87	0.81	0.97	0.96	0.66	1.0	0.82	0.53	-0.32	0.73
Other Assets	0.56	0.71	0.53	0.43	-0.24	0.51	-0.08	0.55	0.65		0.09	0.69	0.42	-0.14	0.41	0.05	0.42	0.28	0.54	0.58	0.5	0.63	0.35	0.31	-0.14	0.37
Long Term Debt	0.16	-0.04	-0.1	0.24	0.1	-0.1	0.16	0.35	0.01	0.09		0.15	0.15	0.32	-0.54	0.65	0.41	-0.03	-0.06	-0.02	0.22	-0.02	-0.09	0.33	0.32	0.28
Net Receivables	0.86	0.9	0.89	0.65	0.0	0.87	-0.38	0.93	0.96	0.69	0.15		0.86	-0.22	0.45	0.52	0.88	0.81	0.92	0.91	0.79	0.96	0.82	0.59	-0.22	0.83
Good Will	0.85	0.79	0.9	0.64	0.37	0.69	-0.63	0.93	0.83	0.42	0.15	0.86		-0.05	0.24	0.5	0.83	0.74	0.89	0.89	0.55	0.85	0.74	0.84	-0.05	0.67
Common Stock Total Equity	0.26	-0.24	-0.34	0.57	0.24	-0.34	0.29	-0.14	-0.32	-0.14	0.32	-0.22	-0.05		-0.27	0.04	-0.18	-0.3	-0.34	-0.31	-0.14	-0.33	-0.3	0.15	1.0	-0.19
Retained Earnings Total Equity	0.41	0.41	0.4	0.32	-0.49	0.73	0.06	0.23	0.51	0.41	-0.54	0.45	0.24	-0.27		-0.31	0.09	0.59	0.42	0.42	0.55	0.5	0.59	-0.16	-0.27	0.43
Short Term Investments	0.43	0.25	0.38	0.38	0.08	0.28	-0.09	0.61	0.38	0.05	0.65	0.52	0.5	0.04	-0.31		0.71	0.4	0.39	0.36	0.48	0.39	0.37	0.42	0.04	0.59
Inventory	0.75	0.79	0.8	0.55	0.26	0.7	-0.51	0.92	0.87	0.42	0.41	0.88	0.83	-0.18	0.09	0.71		0.75	0.86	0.83	0.63	0.86	0.73	0.67	-0.18	0.78
Other Current Assets	0.71	0.69	0.78	0.52	-0.09	0.95	-0.35	0.76	0.81	0.28	-0.03	0.81	0.74	-0.3	0.59	0.4	0.75		0.81	0.78	0.83	0.82	0.97	0.43	-0.3	0.91
Other Stockholder Equity	0.8	0.9	0.99	0.5	0.18	0.82	-0.68	0.9	0.97	0.54	-0.06	0.92	0.89	-0.34	0.42	0.39	0.86	0.81		0.99	0.57	0.98	0.81	0.62	-0.34	0.69
Total Liab	0.8	0.87	0.99	0.51	0.13	0.8	-0.7	0.91	0.96	0.58	-0.02	0.91	0.89	-0.31	0.42	0.36	0.83	0.78	0.99		0.55	0.97	0.78	0.62	-0.31	0.66
Deferred Long Term Liab	0.67	0.59	0.54	0.6	-0.41	0.87	0.13	0.65	0.66	0.5	0.22	0.79	0.55	-0.14	0.55	0.48	0.63	0.83	0.57	0.55		0.66	0.83	0.3	-0.14	0.94
Total Current Assets	0.82	0.92	0.95	0.55	0.06	0.87	-0.55	0.9	1.0	0.63	-0.02	0.96	0.85	-0.33	0.5	0.39	0.86	0.82	0.98	0.97	0.66		0.83	0.55	-0.33	0.73
Short Term Debt	0.72	0.75	0.8	0.53	-0.07	0.95	-0.33	0.72	0.82	0.35	-0.09	0.82	0.74	-0.3	0.59	0.37	0.73	0.97	0.81	0.78	0.83	0.83		0.48	-0.3	0.87
Intangible Assets	0.64	0.66	0.64	0.51	0.64	0.34	-0.6	0.72	0.53	0.31	0.33	0.59	0.84	0.15	-0.16	0.42	0.67	0.43	0.62	0.62	0.3	0.55	0.48		0.15	0.41
Common Stock	0.26	-0.24	-0.34	0.57	0.24	-0.34	0.29	-0.14	-0.32	-0.14	0.32	-0.22	-0.05	1.0	-0.27	0.04	-0.18	-0.3	-0.34	-0.31	-0.14	-0.33	-0.3	0.15		-0.19
Property Plant Equipment	0.7	0.62	0.65	0.58	-0.22	0.89	-0.1	0.78	0.73	0.37	0.28	0.83	0.67	-0.19	0.43	0.59	0.78	0.91	0.69	0.66	0.94	0.73	0.87	0.41	-0.19

Click cells to compare fundamentals

Organogenesis Holdings Account Relationship Matchups

Organogenesis Holdings fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	220.7M	294.5M	443.3M	449.4M	460.0M	292.5M
Other Current Liab	5.8M	24.6M	25.6M	23.8M	13.1M	11.5M
Total Current Liabilities	59.9M	68.2M	82.0M	75.0M	80.5M	48.2M
Total Stockholder Equity	55.6M	146.1M	242.0M	265.7M	278.7M	179.4M
Other Liab	7.7M	15.7M	1.6M	1.1M	1.3M	1.2M
Net Tangible Assets	9.2M	86.7M	187.6M	216.1M	248.5M	261.0M
Retained Earnings	(171.0M)	(153.1M)	(60.1M)	(45.3M)	(41.0M)	(43.0M)
Accounts Payable	28.4M	23.4M	29.3M	32.3M	30.7M	23.8M
Cash	60.2M	84.4M	113.9M	102.5M	104.3M	53.7M
Other Assets	1.6M	688K	33.5M	31.5M	1.0	0.95
Long Term Debt	83.1M	53.0M	70.8M	66.2M	60.7M	65.7M
Net Receivables	39.4M	56.8M	82.5M	89.5M	82.0M	52.7M
Common Stock Total Equity	293.0M	9K	10K	13K	11.7K	11.1K
Inventory	22.9M	27.8M	25.0M	24.8M	28.3M	20.8M
Other Current Assets	3.0M	5.3M	5.6M	5.9M	10.5M	11.0M
Other Stockholder Equity	226.6M	296.8M	302.9M	311.0M	319.6M	181.1M
Total Liab	165.1M	148.4M	201.2M	183.7M	181.4M	113.0M
Deferred Long Term Liab	318K	92K	370K	1.2M	1.4M	1.5M
Total Current Assets	125.6M	174.3M	227.0M	222.6M	225.0M	115.3M
Short Term Debt	3.1M	20.3M	26.6M	16.2M	33.9M	35.6M
Intangible Assets	20.8M	30.6M	25.7M	20.8M	15.9M	22.1M
Common Stock	293.0M	9K	10K	13K	11.7K	11.1K
Property Plant Equipment	47.2M	60.1M	79.2M	102.5M	117.8M	123.7M
Short Long Term Debt Total	100.6M	84.8M	132.3M	123.8M	119.4M	85.3M
Net Debt	40.4M	377K	18.4M	21.3M	15.5M	16.3M
Non Current Assets Total	95.1M	120.2M	216.3M	226.8M	235.0M	196.6M
Non Currrent Assets Other	884K	670K	1.5M	1.5M	6.0M	5.7M
Cash And Short Term Investments	60.2M	84.4M	113.9M	102.5M	104.3M	59.6M
Common Stock Shares Outstanding	92.8M	111.4M	133.7M	132.4M	132.7M	105.4M
Liabilities And Stockholders Equity	220.7M	294.5M	443.3M	449.4M	460.0M	324.6M
Non Current Liabilities Total	105.2M	80.2M	119.2M	108.7M	100.9M	71.7M
Capital Surpluse	226.6M	299.1M	302.2M	311.0M	357.6M	182.7M
Non Current Liabilities Other	6.6M	12.0M	48.5M	42.4M	1.2M	1.2M
Net Invested Capital	138.7M	215.8M	315.5M	336.4M	344.9M	273.1M
Net Working Capital	65.7M	106.1M	145.0M	147.6M	144.5M	95.9M
Property Plant And Equipment Net	47.2M	60.1M	128.3M	145.7M	156.3M	105.8M

Pair Trading with Organogenesis Holdings

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Organogenesis Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Organogenesis Holdings will appreciate offsetting losses from the drop in the long position's value.

Moving against Organogenesis Stock

0.86	TCHH	Trustcash Holdings	Pair Corr
0.79	JNJ	Johnson Johnson Sell-off Trend	Pair Corr
0.78	PFE	Pfizer Inc Fiscal Year End 4th of February 2025	Pair Corr
0.74	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.73	ME	23Andme Holding	Pair Corr

The ability to find closely correlated positions to Organogenesis Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Organogenesis Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Organogenesis Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Organogenesis Holdings to buy it.

The correlation of Organogenesis Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Organogenesis Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Organogenesis Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Organogenesis Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Organogenesis Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Organogenesis Holdings' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Organogenesis Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Organogenesis Holdings Stock:

How To Invest In Organogenesis

Details

Is Organogenesis Stock a good investment?

Details

What is Organogenesis Holdings' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.

You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organogenesis Holdings. If investors know Organogenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organogenesis Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

3.5

Earnings Share

(0.05)

Revenue Per Share

3.446

Quarterly Revenue Growth

0.061

Return On Assets

0.0164

The market value of Organogenesis Holdings is measured differently than its book value, which is the value of Organogenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Organogenesis Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organogenesis Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organogenesis Holdings' market value can be influenced by many factors that don't directly affect Organogenesis Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Organogenesis Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organogenesis Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organogenesis Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Organogenesis Capex To Revenue vs Cost Of Revenue Analysis

Capex To Revenue vs Cost Of Revenue

Capex To Revenue vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Capex To Revenue

Cost Of Revenue

Organogenesis Holdings fundamental ratios Correlations

Organogenesis Holdings Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Organogenesis Holdings fundamental ratios Accounts

Pair Trading with Organogenesis Holdings

Moving against Organogenesis Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash
Common Stock	+ 1.0	Common Stock Total Equity
Other Stockholder Equity	+ 0.99	Total Current Liabilities
Total Liab	+ 0.99	Total Current Liabilities
Total Liab	+ 0.99	Other Stockholder Equity
Total Current Assets	+ 0.98	Other Stockholder Equity

Retained Earnings	- 0.72	Total Current Liabilities
Total Liab	- 0.7	Retained Earnings
Other Stockholder Equity	- 0.68	Retained Earnings
Good Will	- 0.63	Retained Earnings
Intangible Assets	- 0.6	Retained Earnings
Retained Earnings	- 0.58	Other Liab